New immune cell therapy targets relapsed leukemia and MDS
Disease control
Recruiting now
This early-stage study tests a pre-made immune cell therapy (MT-401-OTS) for people aged 65+ with relapsed acute myeloid leukemia or high-risk myelodysplastic syndromes. The therapy uses donor T-cells designed to attack multiple cancer-related targets. The main goals are to check…
Phase: PHASE1 • Sponsor: Marker Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC